These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38609322)

  • 1. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
    Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety of the class of JAK inhibitors or tocilizumab compared with TNF inhibitors in patients with rheumatoid arthritis: Systematic review and a traditional and Bayesian network meta-analysis of randomized clinical trials.
    Pugliesi A; Oliveira DGC; Filho VAS; Machado JO; Pereira AG; Bichuette JCS; Sachetto Z; de Carvalho LSF; Bertolo MB
    Semin Arthritis Rheum; 2024 Dec; 69():152563. PubMed ID: 39383617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of proximod, a selective agonist of sphingosine-1-phosphate receptor-1, in healthy volunteers and patients with rheumatoid arthritis: a phase 1, double-blind, randomised, placebo-controlled, ascending dose trial.
    Zhang H; Li Q; Li C; Wu M; Chen H; Li Y; You F; Zhao Y; Jin J; Chen X; Ding Y
    Lancet Rheumatol; 2024 Dec; 6(12):e837-e847. PubMed ID: 39454617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.
    van de Laar CJ; Oude Voshaar MAH; Ten Klooster P; Tedjo DI; Bos R; Jansen T; Willemze A; Versteeg GA; Goekoop-Ruiterman YPM; Kroot EJ; van de Laar M
    RMD Open; 2024 May; 10(2):. PubMed ID: 38816210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Rubin DT; D'Haens G; Reinisch W; Watanabe M; Mehta R; Roblin X; Beales I; Gietka P; Hibi T; Hospodarskyy I; Ritter T; Genovese MC; Kwon P; Santermans E; Le Brun FO; Barron R; Masior T; Danese S
    Lancet Gastroenterol Hepatol; 2024 Dec; ():. PubMed ID: 39637881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.
    Norton H; Sliwinska-Stanczyk P; Hala T; El-Zorkany B; Stockert L; Mundayat R; Wang L; Ritchlin CT
    Rheumatol Ther; 2024 Dec; ():. PubMed ID: 39636343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study.
    Shih PC; Lai CC; Zou QH; Wang SI; Huang XY; Wei JCC
    Clin Exp Med; 2024 Aug; 24(1):186. PubMed ID: 39133368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard- versus extended-duration anticoagulation for primary venous thromboembolism prophylaxis in acutely ill medical patients.
    Kolkailah AA; Abdelghaffar B; Elshafeey F; Magdy R; Kamel M; Abuelnaga Y; Nabhan AF; Piazza G
    Cochrane Database Syst Rev; 2024 Dec; 12(12):CD014541. PubMed ID: 39629741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis.
    Zhang Q; McDermott GC; Juge PA; Chang SH; Vanni KM; Qian G; Bade KJ; Mueller KT; Kowalski EN; Saavedra AA; Sparks JA
    Semin Arthritis Rheum; 2024 Dec; 69():152561. PubMed ID: 39413452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease.
    Redfern J; Tu Q; Hyun K; Hollings MA; Hafiz N; Zwack C; Free C; Perel P; Chow CK
    Cochrane Database Syst Rev; 2024 Mar; 3(3):CD011851. PubMed ID: 38533994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study.
    Shih PC; Hung PC; Leong PY; Hsu JN; Yang CC; Wei JCC; Chen HH
    Clin Rheumatol; 2024 Dec; 43(12):3625-3637. PubMed ID: 39392514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
    Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
    Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.
    Chowdary P; Angchaisuksiri P; Apte S; Astermark J; Benson G; Chan AKC; Jiménez Yuste V; Matsushita T; Høgh Nielsen AR; Sathar J; Sutton C; Šaulytė Trakymienė S; Tran H; Villarreal Martinez L; Wheeler AP; Windyga J; Young G; Thaung Zaw JJ; Eichler H
    Lancet Haematol; 2024 Dec; 11(12):e891-e904. PubMed ID: 39521008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group.
    Gupta AA; Xue W; Harrison DJ; Hawkins DS; Dasgupta R; Wolden S; Shulkin B; Qumseya A; Routh JC; MacDonald T; Feinberg S; Crompton B; Rudzinski ER; Arnold M; Venkatramani R
    Lancet Oncol; 2024 Jul; 25(7):912-921. PubMed ID: 38936378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.
    Karpouzas GA; Ormseth SR; van Riel PLCM; Gonzalez-Gay MA; Corrales A; Rantapää-Dahlqvist S; Sfikakis PP; Dessein P; Tsang L; Hitchon C; El-Gabalawy H; Pascual-Ramos V; Contreras-Yáñez I; Colunga-Pedraza IJ; Galarza-Delgado DA; Azpiri-Lopez JR; Semb AG; Misra DP; Hauge EM; Kitas G
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39043615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.